Schrödinger, Inc. (NASDAQ:SDGR) Q1 2024 Earnings Call Transcript

Karen Akinsanya: Sure. Yes, so you’re right. The NLRP3 and PRMT5-MTA have been pretty interesting over the last year with a lot of disclosures from other companies. We are excited about both programs. I think what they both have in common is that there are a number of potential indications. So NLRP3 potential, obviously, in Parkinson’s disease, as well as a number of peripheral inflammatory diseases. For PRMT5, there’s opportunity in the brain, in brain tumors, but also a number of solid tumors. So we are excited to have both of these programs in our portfolio. They’re both in the optimization stage. We’re working hard on the optimization of multiple theories. I think we described that at Pipeline Day. And one of the important features is the opportunity to leverage our platform to optimize brain penetration, which is clearly a key feature for both of these programs.

And that work is underway. I think it’s too early to talk about the sort of picking a horse in the race. I think we’re pleased with the progress that we’re seeing. And then your other question, I think, was whether we would develop these alone or in collaboration with others. I think both opportunities are open to us and we remain sort of open to collaboration discussions. But we also are working right now to think about indications in which we would conduct early clinical trials. So, again, we’ll keep you posted as we make progress with that.

Chris Shibutani: Thank you for all the answers to all my questions. Appreciate it.

Operator: I am showing no further questions at this time. That concludes today’s call. You may now disconnect.